Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical

Read Story

Kevin Harrington Becomes The Latest ‘Shark Tank’ Judge To Enter The Psychedelics Space

Read Story

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Read Story

Armed With Two Patents,
Psycheceutical Plans To Transform
Psychedelic Drug Delivery

Read Story

Psycheceutical Licenses New
Delivery Technologies For
Psychedelic Medicines

Read Story

Biotech Company Earns Two
Patents for Targeted Delivery
of Psychedelic Medicines

Read Story

Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption

Read Story

Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents

Read Story

Psycheceutical Welcomes Translational Research Expert Zachary Clayton To Its Advisory Board

Read Story


Psycheceutical’s Chad Harman On The Vine Podcast Ep. #52

Mike “Zappy” Zapolin On The Field Tripping Podcast Ep. #33

Psycheceutical, Bringing Psychedelic Therapies to Market by Developing Unique Delivery Technologies


May 10, 2022 in Press Releases

Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor

Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.
Read More
March 29, 2022 in Press Releases

Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis

Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31…
Read More
March 15, 2022 in Press Releases

Psycheceutical Announces Agreement with Vici Health Sciences

Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development.…
Read More
March 1, 2022 in Press Releases

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.
Read More
January 20, 2022 in Press Releases

Psycheceutical Completes Acquisition by Blue Water Ventures International

Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
Read More
November 18, 2021 in Press Releases

Psycheceutical Grows Scientific Advisory Board With Addition of Translational Research Expert, Zachary Clayton, PhD

Psycheceutical, Inc., today announced the addition of Zachary Clayton, PhD, to its scientific advisory board.
Read More
September 28, 2021 in Press Releases

Psycheceutical, Inc. Expands Executive Team With Announcement of New Advisory Board Appointments

Psycheceutical, Inc., today announced the growth of its esteemed board with two new appointments, Dr. Ronald Aung-Din and Dr. John Kutzko.
Read More
August 19, 2021 in Press Releases

Psycheceutical, Inc. Announces New Patents That Enable Psychedelic Compounds to Be Administered as Pharmaceutical Medicines

Psycheceutical, Inc., today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds.
Read More


Kaia Roman

VP, Strategy & Communications